How big is Lipocine, Inc.?

As of Jun 18, Lipocine, Inc. has a market capitalization of 16.79 million, with net sales of 3.67 million and a net profit of -5.37 million over the latest four quarters. The company reported shareholder's funds of 21.00 million and total assets of 22.51 million as of Dec 24.

Market Cap: As of Jun 18, Lipocine, Inc. has a market capitalization of 16.79 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lipocine, Inc. reported net sales of 3.67 million and a net profit of -5.37 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 21.00 million and total assets of 22.51 million.

What does Lipocine, Inc. do?

Lipocine, Inc. is a clinical-stage biopharmaceutical company specializing in oral drug delivery technologies. As of March 2025, it has a market cap of $16.79 million, with net sales of $0 million and a net loss of $2 million.

Overview: <BR>Lipocine, Inc. is a clinical-stage biopharmaceutical company focused on developing oral drug delivery technologies for pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 16.79 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -28.27% <BR>Price to Book: 0.87<BR><BR>Contact Details: <BR>Address: 675 S Arapeen Dr Ste 202, SALT LAKE CITY UT: 84108-1295 <BR>Tel: 1 801 9947383 <BR>Fax: 1 801 9947388 <BR>Website: https://www.lipocine.com/

Should I buy, sell or hold Lipocine, Inc.?

Who are in the management team of Lipocine, Inc.?

As of March 2022, Lipocine, Inc.'s management team includes Dr. Mahesh Patel as Chairman, President, and CEO, with Dr. Stephen Hill as Lead Independent Director, and board members Mr. John Higuchi, Mr. Jeffrey Fink, and Dr. Richard Ono.

As of March 2022, the management team of Lipocine, Inc. includes Dr. Mahesh Patel, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Dr. Stephen Hill is the Lead Independent Director. Other members of the board include Mr. John Higuchi as a Director, Mr. Jeffrey Fink as an Independent Director, and Dr. Richard Ono also serving as an Independent Director.

Is Lipocine, Inc. overvalued or undervalued?

As of May 8, 2025, Lipocine, Inc. is considered a risky investment due to its overvaluation and poor performance metrics, including a Price to Book Value of 0.88 and significant underperformance against the S&P 500, with a year-to-date return of -42.42%.

As of 8 May 2025, the valuation grade for Lipocine, Inc. has moved from fair to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, particularly given its negative performance metrics and ratios. Key valuation ratios include a Price to Book Value of 0.88, an EV to EBIT of 0.42, and an EV to EBITDA of 0.43, which reflect significant concerns about its financial health and operational efficiency.<BR><BR>In comparison to peers, Lipocine's valuation is notably weaker; for instance, Lisata Therapeutics, Inc. has an EV to EBITDA of 0.1349, while Oncternal Therapeutics, Inc. stands at 0.3568. The stark contrast in these ratios highlights Lipocine's precarious position in the industry. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -42.42% compared to the index's 12.22%, reinforcing the notion that Lipocine is currently overvalued.

Is Lipocine, Inc. technically bullish or bearish?

As of September 8, 2025, Lipocine, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, and has underperformed the S&P 500 with a year-to-date return of -42.42%.

As of 8 September 2025, the technical trend for Lipocine, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and bearish signals from Bollinger Bands and KST. Daily moving averages also indicate a bearish trend. The Dow Theory shows a mildly bearish stance on the monthly timeframe, while the On-Balance Volume (OBV) presents a mildly bearish signal weekly but mildly bullish monthly. <BR><BR>In terms of performance, Lipocine has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -42.42% compared to the S&P 500's 12.22%, and a one-year return of -43.91% versus 17.14%.